The Netherlands Cancer Institute (NKI), the country’s leading cancer research centre, has invested in Senya Therapeutics

Learn more

New findings on LRG1’s role in retinal disease published in Science Translational Medicine

Learn more

Dr. Chris Martin Joins Senya’s Board as a Non-Executive Director

Learn more

Senya and Imperial College London Collaborate on Chronic Kidney Disease Research

Learn more

Senya and University of Edinburgh Partner on Nephrology Research

Learn more

Senya Completes £1.8M Seed Extension Round

Learn more

Senya and Netherlands Cancer Institute (NKI) Collaborate on Cancer Research

Learn more

Senya and Netherlands Cancer Institute (NKI) Sign R&D Collaboration Agreement

Learn more

Senya Wins £0.7M Innovate UK Grant

Learn more

Senya Secures Exclusive Rights to LRG1-Related Patents

Learn more